Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Repeat Alefacept Courses in Chronic Plaque Psoriasis
NCT00233662Phase 3Completed
- Sponsor
- Biogen
- Start
- Dec 2002
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of alefacept in psoriasis, sponsored by Biogen. Primary endpoints: Incidence of infections, Incidence of malignancies and 4 more. Started Dec 2002; status: completed.
02
Drugs
alefacept
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT00233662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00233662.